Ocular Therapeutix (OCUL) Accumulated Expenses (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Accumulated Expenses of $39.1 million for Q2 2026, up 13.48% year-over-year from $34.4 million in Q2 2025, and up 7.04% on a QoQ basis from $36.5 million in Q1 2026.
Ocular Therapeutix (OCUL) Accumulated Expenses (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Accumulated Expenses for 14 years, with the latest figure at $39.1 million in Q2 2026.
- Accumulated Expenses for Q2 2026 came in at $39.1 million, up 13.48% year-over-year; the trailing twelve-month figure through Jun 2026 was $39.1 million (up 13.48% YoY), and the FY2025 annual result was $43.8 million, up 24.83% from the prior year.
- Accumulated Expenses climbed to $39.1 million in Q2 2026, from $36.5 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $43.8 million in Q4 2025 and troughed at $16.0 million in Q1 2024.
- A 5-year average of $28.8 million and a median of $28.8 million in 2023 frame the typical range for Accumulated Expenses.
- The widest annual swing landed in 2024, when Accumulated Expenses retreated 27.07%; it then surged 93.77% in 2025.
- A 5-year view of Accumulated Expenses shows it stood at $24.1 million in 2022, then gained by 18.96% to $28.7 million in 2023, then rose by 22.5% to $35.1 million in 2024, then rose by 24.83% to $43.8 million in 2025, then slipped by 10.9% to $39.1 million in 2026.
- Per Business Quant data, the three most recent Accumulated Expenses figures were $39.1 million in Q2 2026, $36.5 million in Q1 2026, and $43.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.06 Mn |
| Mar 31, 2026 | 36.49 Mn |
| Dec 31, 2025 | 43.84 Mn |
| Sep 30, 2025 | 40.27 Mn |
| Jun 30, 2025 | 34.42 Mn |
| Mar 31, 2025 | 8.38 Mn |
| Dec 31, 2024 | 35.12 Mn |
| Sep 30, 2024 | 30.45 Mn |
| Jun 30, 2024 | 8.44 Mn |
| Mar 31, 2024 | 5.37 Mn |
| Dec 31, 2023 | 8.16 Mn |
| Sep 30, 2023 | 28.89 Mn |
| Jun 30, 2023 | 6.24 Mn |
| Mar 31, 2023 | 21.99 Mn |
| Dec 31, 2022 | 24.10 Mn |
| Sep 30, 2022 | 21.61 Mn |
| Jun 30, 2022 | 4.75 Mn |
| Mar 31, 2022 | 3.52 Mn |
| Dec 31, 2021 | 20.12 Mn |
| Sep 30, 2021 | 19.36 Mn |